US Stock MarketDetailed Quotes

RXRX Recursion Pharmaceuticals

Watchlist
  • 10.530
  • +2.030+23.88%
Close Feb 14 16:00 ET
  • 11.000
  • +0.470+4.46%
Post 19:59 ET
4.11BMarket Cap-6.84P/E (TTM)

About Recursion Pharmaceuticals Company

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Company Profile

SymbolRXRX
Company NameRecursion Pharmaceuticals
Listing DateApr 16, 2021
Issue Price18.00
Founded2013
CEODr. Christopher Gibson, PhD
MarketNASDAQ
Employees500
Fiscal Year Ends12-31
Address41 South Rio Grande Street
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84101
Phone1-385-269-0203

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Christopher Gibson, PhD
  • Chief Executive Officer, Director and President
  • 8.61M
  • Kristen Rushton
  • Chief Operating Officer
  • --
  • Matthew Kinn
  • Chief Business Officer
  • --
  • David Hallett, PhD
  • Chief Scientific Officer
  • --
  • Dr. David J. Mauro, M.D.
  • Chief Medical Officer
  • 4.31M
  • Dr. Najat Khan, PhD
  • Director, Chief Research and Development Officer and Chief Commercial Officer
  • --
  • Ben R. Taylor
  • Chief Financial Officer and President, Recursion UK
  • --
  • Lina Nilsson
  • Senior Vice President and Head, Platform
  • --
  • Dr. Robert M. Hershberg, M.D.,PhD
  • Chairman of the Board
  • 302.74K
  • Dr. Franziska Michor, PhD
  • Director
  • --
  • Zachary Bogue, J.D.
  • Independent Director
  • 21.25K
  • Dr. Blake Borgeson, PhD
  • Independent Director
  • 292.74K
  • Dean Y. Li, M.D.,PhD
  • Independent Director
  • 300.25K
  • Zavain Dar, PhD
  • Independent Director
  • 307.74K

Trending Stocks

Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More